3+ 4/2002 - Společnost pro pojivové tkáně

Conclusions: PCH was effective in short term treatment, its effect started later on than
that of DCF and this benefit lasted for a long period after its administration was withdrawn
Key words: bone form osteoarthritis, pharmaceutical grade collagen hydrolysate,
diclofenac, urinary pyridinoline, chondrex, bone alkaline phosphatase
INTRODUCTION
In the last decades interest is paid to
nutritional supplements (Nutraceuticals)
especially to hydrolyzed collagen, both as
symptomatic relieving agents, and agents
which may have a specific effect on
osteoarthritis pathophysiology and pathologic
structural changes. The prospective
study of Promislow et al. (2002) supports
the possibility of a positive role for dietary
animal protein in the skeletal health.
Hydrolyzed gelatine derivatives, which are
manufactured from bovine or porcine hide
or bones, have been used over many centuries
and are generally, recognized as safe
food products. Pharmaceutical grade with
collagen hydrolysate (PCH) is a soluble
powder obtained using an enzymatic digestion
a food approved enzyme. The average
molecular mass ranges from 500 to 6000.
Clinical studies of these derivatives
showed efficacious symptomatic effect in
osteoarthritis (Adam, 1991, Moskowitz,
2000). No side effects were observed previously
(Adam, 1991, Adam et al., 1996, Adam
et al.,1998).Acute,subacute,teratogenic and
mutagenic testing of gelatin hydrolysates did
not revealed any health risk.
Oesser et al. (1999) using radioactively
labelled collagen peptides showed their
passing through gastrointestinal wall. Further
radioactivity in skin attained its peak
value 12 hours after the administration of
the 14C-labeled collagen hydrolysate. Cartilage
accummulated 14C radioactivity much
slower – peak value was reached after 48
62
hours and this niveau of radioactivity was
still present after 96 hours.
The purpose of this study was to assess
the effectiveness of PCH on reducing joint
pain and stiffness, and improving functional
ability of the knee and/or the hip joints in
those suffering from bone form of
osteoarthritis (BOA) over a three months
treatment and to compare it with the effect
of diclofenac.
STUDY DESIGN
LOCOMOTOR SYSTEM vol. 9, 2002, No. 3+4
A 13-week randomized, propective,
double blindtolerability of oral treatment
with PCH versus diclophenac in three agematched
groups of patients.
Patients: A total of 46 patients of both
sexes (25 females, 19 males) exhibiting knee
and/or hip pains and OA bone form (BOA)
(Kellgren-Lawrence radiologic severity,
grade 3 or 4) of hip and/or knee (femoro-tibial)
joints were enrolled in this study.
Exclusion criteria: Patients suffering
from neoplasia, peptic gastroduodenal
ulcer, bone metabolic diseases and/or other
metabolic diseases, secondary OA of any
kind, inflammatory joint disease, intraarticular
corticosteroids in the preceding six
months, genu valgum or varum exceeding
80 and any SYSADOA administration in the
preceding 6 months, were excluded. Only
two drop-outs (both on DCF) occurred during
the study, but from other causes than
because of side effects,pain increasing,inefficacy,
and/or compliance.